The document outlines key proteins and pathways involved in B-cell receptor signaling such as CD79, CD19, Syk, PI3K, Lyn, BLNK, BTK, AKT, MTOR, MEK, ERK, CARD11, NF-kB that lead to B-cell survival, growth, proliferation, and microenvironment. It also lists several drugs that inhibit proteins in this pathway including Syk inhibitors Fostamatinib and GS-9973, the BTK inhibitor Ibrutinib and AVL-292, and the PI3K inhibitor Idelalisib.